NT5C2 and acute lymphoblastic leukemia: Certain alterations were found to be associated with resistance against backbone cytoreductive agents in ALL protocols (e.g., CREBBP aberrations predict corticosteroid resistance [106], while some studies suggested that NT5C2 alterations may predispose to poor response to 6-mercaptopurine [105]).